J. M. S. Bartlett

1.6k total citations
34 papers, 1.1k citations indexed

About

J. M. S. Bartlett is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, J. M. S. Bartlett has authored 34 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 15 papers in Cancer Research and 7 papers in Molecular Biology. Recurrent topics in J. M. S. Bartlett's work include Breast Cancer Treatment Studies (13 papers), HER2/EGFR in Cancer Research (10 papers) and Sperm and Testicular Function (5 papers). J. M. S. Bartlett is often cited by papers focused on Breast Cancer Treatment Studies (13 papers), HER2/EGFR in Cancer Research (10 papers) and Sperm and Testicular Function (5 papers). J. M. S. Bartlett collaborates with scholars based in United Kingdom, Canada and India. J. M. S. Bartlett's co-authors include Eberhard Nieschlag, Ian O. Ellis, Mitch Dowsett, Gerhard F. Weinbauer, R A Walker, Sarah E. Pinder, Julie Doughty, Peter Canney, Donald C. McMillan and Chris Wilson and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and The Journal of Urology.

In The Last Decade

J. M. S. Bartlett

34 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
J. M. S. Bartlett United Kingdom 15 681 372 297 276 184 34 1.1k
Stuart McIntosh United Kingdom 20 503 0.7× 264 0.7× 173 0.6× 466 1.7× 456 2.5× 91 1.5k
Mila Pinchev Israel 17 534 0.8× 313 0.8× 124 0.4× 344 1.2× 136 0.7× 30 1.0k
R R Millis United Kingdom 22 830 1.2× 246 0.7× 182 0.6× 664 2.4× 155 0.8× 32 1.5k
Ulla Johansson Sweden 16 598 0.9× 272 0.7× 110 0.4× 493 1.8× 200 1.1× 21 1.1k
Lars Ottestad Norway 15 1.2k 1.8× 488 1.3× 371 1.2× 517 1.9× 263 1.4× 35 1.7k
Anne Irene Hagen Norway 16 564 0.8× 178 0.5× 145 0.5× 411 1.5× 93 0.5× 31 1.2k
Peter C. Willsher United Kingdom 20 629 0.9× 372 1.0× 119 0.4× 390 1.4× 189 1.0× 48 1.3k
Steven T. Brower United States 22 648 1.0× 343 0.9× 79 0.3× 497 1.8× 214 1.2× 47 1.6k
Helena Hwang United States 16 385 0.6× 165 0.4× 133 0.4× 282 1.0× 149 0.8× 38 928
Pentti J. Taskinen Finland 16 465 0.7× 343 0.9× 66 0.2× 310 1.1× 235 1.3× 35 1.3k

Countries citing papers authored by J. M. S. Bartlett

Since Specialization
Citations

This map shows the geographic impact of J. M. S. Bartlett's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. M. S. Bartlett with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. M. S. Bartlett more than expected).

Fields of papers citing papers by J. M. S. Bartlett

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. M. S. Bartlett. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. M. S. Bartlett. The network helps show where J. M. S. Bartlett may publish in the future.

Co-authorship network of co-authors of J. M. S. Bartlett

This figure shows the co-authorship network connecting the top 25 collaborators of J. M. S. Bartlett. A scholar is included among the top collaborators of J. M. S. Bartlett based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. M. S. Bartlett. J. M. S. Bartlett is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Stein, Robert C., A. Marshall, Luke Hughes‐Davies, et al.. (2025). 190O Clinical outcomes in the OPTIMA prelim (Optimal Personalised Treatment of early breast cancer using Multi-Parameter Analysis) feasibility study. ESMO Open. 10. 104744–104744. 1 indexed citations
2.
Blanchette, Phillip, Danielle Desautels, Gregory R. Pond, et al.. (2018). Factors influencing survival among patients with HER2-positive metastatic breast cancer treated with trastuzumab. Breast Cancer Research and Treatment. 170(1). 169–177. 14 indexed citations
3.
Stein, Robert C., Luke Hughes‐Davies, J. M. S. Bartlett, et al.. (2015). 1809 Results of the OPTIMA (Optimal Personalized Treatment of early breast cancer usIng Multi-parameter Analysis) prelim study. European Journal of Cancer. 51. S268–S268. 2 indexed citations
4.
Stephen, Jacqueline, Gordon Murray, David Cameron, et al.. (2014). Time dependence of biomarkers: non-proportional effects of immunohistochemical panels predicting relapse risk in early breast cancer. British Journal of Cancer. 111(12). 2242–2247. 10 indexed citations
5.
6.
Bartlett, J. M. S., Jane Starczynski, Neil Atkey, et al.. (2011). HER2 testing in the UK: recommendations for breast and gastric in-situ hybridisation methods. Journal of Clinical Pathology. 64(8). 649–653. 56 indexed citations
7.
Baneshi, Mohammad Reza, Pamela Warner, Niall Anderson, et al.. (2010). Tamoxifen resistance in early breast cancer: statistical modelling of tissue markers to improve risk prediction. British Journal of Cancer. 102(10). 1503–1510. 14 indexed citations
8.
Bartlett, J. M. S., et al.. (2010). Integrated river basin management in Southeast Asia. Journal of Flood Risk Management. 3(3). 201–209. 8 indexed citations
9.
Munro, Alison F., David Cameron, Jeremy Thomas, Chris Twelves, & J. M. S. Bartlett. (2009). BUBR1 and MAD2: Novel Markers for Predicting Benefit from Adjuvant Anthracyclines?. Cancer Research. 69(24_Supplement). 2124–2124. 2 indexed citations
10.
Walker, R A, J. M. S. Bartlett, Mitch Dowsett, et al.. (2008). HER2 testing in the UK: further update to recommendations. Journal of Clinical Pathology. 61(7). 818–824. 98 indexed citations
11.
Mitra, Anita, Cyril Fisher, Christopher S. Foster, et al.. (2008). Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype. British Journal of Cancer. 98(2). 502–507. 109 indexed citations
12.
Faratian, Dana & J. M. S. Bartlett. (2007). Predictive markers in breast cancer – the future. Histopathology. 52(1). 91–98. 30 indexed citations
13.
Bartlett, J. M. S., et al.. (2006). Evaluation of an inflammation-based prognostic score (GPS) in patients with metastatic breast cancer. British Journal of Cancer. 94(2). 227–230. 182 indexed citations
14.
Bartlett, J. M. S.. (2001). Technology evaluation: SAGE, Genzyme molecular oncology.. PubMed. 3(1). 85–96. 12 indexed citations
15.
Bartlett, J. M. S., A.D. Watters, S Ballantyne, et al.. (1999). Is Chromosome 9 Loss a Marker of Disease Recurrence in Transitional Cell Carcinoma of the Urinary Bladder?. The Journal of Urology. 161(2). 716–716. 7 indexed citations
16.
Underwood, Mark A., et al.. (1996). Overexpression of p53 protein and its significance for recurrent progressive bladder tumours. British Journal of Urology. 77(5). 659–666. 29 indexed citations
17.
18.
Bartlett, J. M. S., et al.. (1991). Regulation of testicular insulin-like growth factor-I in pubertal growth hormone-deficient male rats. Journal of Endocrinology. 131(2). 279–285. 24 indexed citations
19.
Bartlett, J. M. S., et al.. (1991). Hormonal regulation of epidermal growth factor and insulinlike growth factor-I in adult male hypophysectomized rats treated with ethane dimethane sulphonate. Journal of Endocrinology. 129(1). 109–117. 15 indexed citations
20.
Bartlett, J. M. S., Gerhard F. Weinbauer, & Eberhard Nieschlag. (1990). Stability of Spermatogenic Synchronization Achieved by Depletion and Restoration of Vitamin A in Rats. Biology of Reproduction. 42(4). 603–612. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Stuart McIntosh Breakdown of academic impact, for papers by Mila Pinchev Breakdown of academic impact, for papers by R R Millis Breakdown of academic impact, for papers by Ulla Johansson Breakdown of academic impact, for papers by Lars Ottestad Breakdown of academic impact, for papers by Anne Irene Hagen Breakdown of academic impact, for papers by Peter C. Willsher Breakdown of academic impact, for papers by Steven T. Brower Breakdown of academic impact, for papers by Helena Hwang Breakdown of academic impact, for papers by Pentti J. Taskinen
Rankless by CCL
2026